Evidence map›Paper›PMID 31917184›Full record

ArticleJournal of clinical lipidology

Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.

Marja-Riitta Taskinen, Elias Björnson, Linda Andersson, Juhani Kahri, Kimmo Porthan, Niina Matikainen, Sanni Söderlund, Kirsi Pietiläinen, Antti Hakkarainen, Nina Lundbom and 6 more

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02948777. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02948777 phase4completed

Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

Ran2016Enrolled14Registered outcomes25Posted comparisons24ConditionsType 2 Diabetes MellitusArmsEvolocumab
PMID 33356392PMID 221537PMID 30779243other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap.European heart journal supplements : journal of the European Society of Cardiology · 2020
    Article
  8. Causes and Consequences of Hypertriglyceridemia.Frontiers in endocrinology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Marja-Riitta TaskinenResearch Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland.
Elias BjörnsonDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden.
Linda AnderssonDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden.
Juhani KahriResearch Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland; Department of Internal Medicine and Rehabilitation, Helsinki University Hospital, Helsinki, Finland.
Kimmo PorthanResearch Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland.
Niina MatikainenResearch Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland; Endocrinology, Abdominal Center, Helsinki University Hospital, Helsnki, Finland.
Sanni SöderlundResearch Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland; Endocrinology, Abdominal Center, Helsinki University Hospital, Helsnki, Finland.
Kirsi PietiläinenResearch Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland; Endocrinology, Abdominal Center, Helsinki University Hospital, Helsnki, Finland.
Antti HakkarainenRadiology, HUS Medical Imaging Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Nina LundbomRadiology, HUS Medical Imaging Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Ralf NilssonDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Marcus StåhlmanDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden.
Martin AdielsDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden.
Paolo PariniDepartment of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden; Theme Inflammation and Infection, Karolinska University Hospital, Stockholm, Sweden.
Chris PackardInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Jan BorénDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Sweden; Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: jan.boren@wlab.gu.se.
University of Helsinki · FIUniversity of Gothenburg · SEHelsinki University Hospital · FIAstraZeneca (Sweden) · SEKarolinska Institutet · SESahlgrenska University Hospital · SEUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) significantly lower the levels of low-density lipoprotein and very-low-density lipoproteins (VLDL), but their effect on postprandial lipoprotein metabolism in dyslipidemic subjects is unclear.

objectiveThis study aimed to investigate the effects of evolocumab on postprandial lipid responses, ectopic fat depots, whole-body cholesterol synthesis, hepatic lipogenesis, and fat oxidation in patients with type II diabetes.

methodsThe trial was a single-phase, nonrandomized study of 12-week treatment with evolocumab 140 mg subcutaneously every 2 weeks in 15 patients with type II diabetes on background statin therapy. Cardiometabolic responses to a high-fat mixed meal were assessed before and at the end of the intervention period.

resultsEvolocumab treatment reduced significantly postprandial rises in plasma total triglyceride (by 21%; P < .0001) and VLDL

conclusionEvolocumab treatment improved postprandial responses of triglyceride-rich lipoproteins and measures of cholesterol-enriched remnant particles in type II diabetic subjects. These results indicate that postprandial phenomena need to be taken into account in assessing the full range of actions of PCSK9 inhibitors in dyslipidemic individuals.

Indexed as

AdultAntibodies, Monoclonal, HumanizedCholesterolChylomicronsDiabetes Mellitus, Type 2FemaleHumansLipoproteinsLipoproteins, VLDLMaleMiddle AgedPCSK9 InhibitorsPostprandial PeriodProprotein Convertase 9TriglyceridesAntibodies, Monoclonal, HumanizedCholesterolChylomicronsevolocumabLipoproteinsLipoproteins, VLDLlipoprotein triglyceridePCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9remnant-like particle cholesterolTriglyceridesapoBApolipoprotein C3Atherogenic dyslipidemiaDe novo lipogenesisEvolocumabLiver fatPCSK9Postprandial lipidsRemnant lipoproteins

Identifiers

PMID31917184
OpenAlexW2996659077

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.